- Home
- SNBR vs CGTX Comparison
SNBR vs CGTX Comparison
Compare SNBR & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SNBR | CGTX |
|---|---|---|
| Founded | 1987 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.2M | 94.5M |
| IPO Year | 1998 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SNBR | CGTX |
|---|---|---|
| Price | $4.59 | $1.14 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $10.00 | $3.33 |
| AVG Volume (30 Days) | ★ 683.0K | 624.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,682,296,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.49 | $0.22 |
| 52 Week High | $13.94 | $3.83 |
Technical Indicators
Market Signals| Indicator | SNBR | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 24.51 | 52.08 |
| Support Level | $3.73 | $1.00 |
| Resistance Level | $8.94 | $1.19 |
| Average True Range (ATR) | 0.67 | 0.07 |
| MACD | -0.26 | 0.02 |
| Stochastic Oscillator | 0.31 | 80.56 |
Price Performance
Historical ComparisonAbout SNBR Sleep Number Corporation
Sleep Number Corp. is a wellness technology company engaged in the design, manufacturing, marketing and distribution of sleep solutions. The Company generates revenue by marketing and selling its smart beds directly to new and existing customers through its vertically integrated, exclusive, direct-to-consumer retail touch points including Stores, Online, Phone, and Chat (Total Retail). The products offered by the company are Mattresses, Bedding, Pillows and Furniture.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.